Trials / Conditions / Cholangiocarcinoma Non-resectable

Cholangiocarcinoma Non-resectable

20 registered clinical trials studyying Cholangiocarcinoma Non-resectable — 10 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	Preoperative Right Hepatic Artery Embolization for Locally Advanced Bismuth IIIb and IV Perihilar Cholangiocar NCT07326189	Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	N/A
Not Yet Recruiting	TRACE-BTC. Relation of Biomarkers and Patients Reported Quality of Life to Outcomes in Patients With Biliary T NCT07454486	Aarhus University Hospital	—
Recruiting	CT-95 in Advanced Cancers Associated With Mesothelin Expression NCT06756035	Context Therapeutics Inc.	Phase 1
Recruiting	En Bloc Resection of the Liver and Pancreas With a "Non-touch" Technique Followed by Liver Transplantation to NCT06850753	Oslo University Hospital	N/A
Recruiting	Combined HAIC, Lenvatinib and Pucotenlimab As Conversion Therapy for Unresectable Intrahepatic Cholangiocarcin NCT06192797	Tongji Hospital	Phase 2
Recruiting	Y-90 With Durvalumab/Gem/Cis in Intrahepatic Cholangio NCT05655949	Beth Israel Deaconess Medical Center	Phase 2
Unknown	Combined DEB-TACE, Lenvatinib and Pucotenlimab as Conversion Therapy for Unresectable Intrahepatic Cholangioca NCT06192784	Tongji Hospital	Phase 2
Active Not Recruiting	A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholang NCT06081829	Servier	Phase 2
Enrolling By Invitation	Primary Percutaneous Stenting Above the Ampulla Versus Endoscopic Drainage for Unresectable Malignant Hilar Bi NCT06671418	Erasmus Medical Center	Phase 3
Recruiting	Cadonilimab With Chemotherapy in Treating Advanced Biliary Cancer NCT05978609	West China Hospital	Phase 2
Unknown	DEB-TACE, Lenvatinib and Anti-PD(L)1 Antibody as Conversion Therapy for Intrahepatic Cholangiocarcinoma NCT06194695	Ze-yang Ding, MD	—
Completed	Photodynamic Therapy for Cholangiocarcinoma NCT04860154	Hepatopancreatobiliary Surgery Institute of Gansu Province	N/A
Recruiting	TACE Combined With Immune Checkpoint Inhibitors for Liver Malignant Tumors NCT06487663	Tianjin Medical University Cancer Institute and Hospital	N/A
Recruiting	Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable In NCT03364530	University Hospital, Montpellier	Phase 2
Completed	Durvalumab and Tremelimumab With Gemcitabine or Gemcitabine/Cisplatin Compared to Gemcitabine/Cisplatin in CCA NCT03473574	AIO-Studien-gGmbH	Phase 2
Completed	A Study of ABC294640 Alone and in Combination With HCQ Sulfate in the Treatment of Advanced Cholangiocarcinoma NCT03377179	RedHill Biopharma Limited	Phase 2
Completed	Nal-IRI and 5-FU Compared to 5-FU in Patients With Cholangio- and Gallbladder Carcinoma Previously Treated Wit NCT03043547	AIO-Studien-gGmbH	Phase 2
Terminated	Study of PEGPH20 With Cisplatin (CIS) and Gemcitabine (GEM); PEGPH20 With Atezolizumab (ATEZO), CIS, and GEM; NCT03267940	Halozyme Therapeutics	Phase 1
Terminated	RFA RCT for Pancreatic or Bile Duct Cancer NCT02166190	Weill Medical College of Cornell University	N/A
No Longer Available	Expanded Access for the Treatment of Advanced Cholangiocarcinoma With ABC294640 (Yeliva ®) NCT03414489	RedHill Biopharma Limited	—